Benign Conditions

Latest News



The recently concluded AUA annual meeting in Orlando may not go down as one of the most memorable annual meetings in recent years. Nevertheless, it was noteworthy for some interesting news and lively debate on hot-button topics: the safety of certain urologic products, namely, testosterone and transvaginal mesh; new tests for prostate cancer; infection prevention and treatment; and use of an advanced prostate cancer agent in the pre-chemotherapy setting.

Analyses of serial magnetic resonance imaging and three-dimensional renderings of those images provide proof of principle for using convective thermal heating to ablate prostate tissue, and early evidence suggests the efficacy and potential clinical advantages of using this novel technology to treat BPH, said first author Lance A. Mynderse, MD, at the European Association of Urology annual congress in Stockholm, Sweden.

This list of U.S.-based National Institutes of Health trials is derived from the NIH’s database and includes phase I-IV hypogonadism and BPH trials that are currently recruiting participants.

Intravesical administration of a liquid liposomal formulation of onabotulinumtoxinA (“Liposomal BoNT-A,” Lipella Pharmaceuticals) shows promise as a safe and effective treatment for refractory overactive bladder (OAB), according to a pilot study presented at the European Association of Urology annual congress in Stockholm, Sweden.

Laser photoselective vaporization prostatectomy is permitting surgical intervention for BPH in a widening array of patients, many of whom harbor comorbidities that would ordinarily exclude them from invasive procedures, according to a new multinational report.